Gapping down
In reaction to disappointing earnings/guidance: ISRG -9.8% (also initiated with an Underperform at Sterne Agee), MG -4.4%, SAIC -2.7% (light volume), WDFC -1.1% (light volume), HCLP -0.8% (also announces acquisition of Augusta Facility and provides updated guidance for Q1; Co sees Q1 EBITDA of $18.8-19.5 mln; announces primary offering of 4.25 mln common units).
Select metals/mining stocks trading lower: HMY -1.9%, SLV -1.2%, AU -0.9%, ABX -1%, GDX -0.7%, SLW -0.5%, GG -0.5%, GOLD -0.4%, NEM -0.4%.
Coal names lower following downgrades: ACI -3.5% (downgraded to Sell from Neutral at UBS), ANR -2.5% (downgraded to Sell from Neutral at UBS; tgt lowered to $3 from $5 ), WLT -1.2% (downgraded to Sell from Neutral at UBS)
Other news: RLYP -7.1% (commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $80 million), AVIV -3.9% (commenced an underwritten public offering of 8 mln shares of its common stock), AHT -3.8% (announces offering of 7 mln shares of common stock), HALO -3.5% (announced that the United States Food and Drug Administration informed the co yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer), LJPC -3.4% (following late move higher -- was up more than 12% on the day), GM -2.4% ( fined $28k by NHTSA; also General Motors is late in ignition switch fix deliveries, according to reports; downgraded to Underweight from Equal-Weight at Morgan Stanley ), TM -1.8% (Toyota Motor announces new recalls ), AAL -1.1% (announces ~17.2 mln shares of convertible preferred stock will be converted into common stock as of close of business April 8, 2014), CHS -1% (late move higher after Leonard Green discloseD new position in amended 13F; adds 2.05 mln shares; filing is as of 12/31/13), IMGN -0.9% (announces first clinical findings with refined dosing strategy for IMGN853: Initial Findings Show New Dosing Approach for IMGN853 Achieves Objective).
Analyst comments: FNFG -2.8% (downgraded to Underweight from Overweight at Barclays; tgt lowered to $9 from $11), ARO -2.2% (downgraded to Underweight from Neutral at Piper Jaffray ), HSY -1.2% (downgraded to Sell from Neutral at Goldman), ENL -0.8% (downgraded to Underperform from Neutral at Exane BNP Paribas), APA -0.7% (downgraded to Hold from Buy at Deutsche Bank), F-0.3% (estimates and target lowered to $17 at Morgan Stanley), CS -0.2% (downgraded to Underweight from Neutral at JP Morgan)
Select metals/mining stocks trading lower: HMY -1.9%, SLV -1.2%, AU -0.9%, ABX -1%, GDX -0.7%, SLW -0.5%, GG -0.5%, GOLD -0.4%, NEM -0.4%.
Coal names lower following downgrades: ACI -3.5% (downgraded to Sell from Neutral at UBS), ANR -2.5% (downgraded to Sell from Neutral at UBS; tgt lowered to $3 from $5 ), WLT -1.2% (downgraded to Sell from Neutral at UBS)
Other news: RLYP -7.1% (commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $80 million), AVIV -3.9% (commenced an underwritten public offering of 8 mln shares of its common stock), AHT -3.8% (announces offering of 7 mln shares of common stock), HALO -3.5% (announced that the United States Food and Drug Administration informed the co yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer), LJPC -3.4% (following late move higher -- was up more than 12% on the day), GM -2.4% ( fined $28k by NHTSA; also General Motors is late in ignition switch fix deliveries, according to reports; downgraded to Underweight from Equal-Weight at Morgan Stanley ), TM -1.8% (Toyota Motor announces new recalls ), AAL -1.1% (announces ~17.2 mln shares of convertible preferred stock will be converted into common stock as of close of business April 8, 2014), CHS -1% (late move higher after Leonard Green discloseD new position in amended 13F; adds 2.05 mln shares; filing is as of 12/31/13), IMGN -0.9% (announces first clinical findings with refined dosing strategy for IMGN853: Initial Findings Show New Dosing Approach for IMGN853 Achieves Objective).
Analyst comments: FNFG -2.8% (downgraded to Underweight from Overweight at Barclays; tgt lowered to $9 from $11), ARO -2.2% (downgraded to Underweight from Neutral at Piper Jaffray ), HSY -1.2% (downgraded to Sell from Neutral at Goldman), ENL -0.8% (downgraded to Underperform from Neutral at Exane BNP Paribas), APA -0.7% (downgraded to Hold from Buy at Deutsche Bank), F-0.3% (estimates and target lowered to $17 at Morgan Stanley), CS -0.2% (downgraded to Underweight from Neutral at JP Morgan)